glp-1/gip dual agonist lilly The U.S. Food and Drug Administration approved Eli Lilly's GLP-1 pill, the company said, a major milestone for the Indianapolis-based drugmaker and one that will test the market for new weight-loss medications Design of a novel long-acting

They added BPC-157 to Category 2 of substances presenting significant safety risks, noting concerns about immune reactions, peptide impurities, and lack of safety data for any human use

In addition, levocarnitine buffers excess intramitochondrial acyl-CoA, regenerating free coenzyme A and potentially preventing inhibition of critical metabolic enzymes

They are typically used alongside dietary modification and other antidiabetic medicines as part of a broader management plan

Investors appeared disappointed by CagriSemas Phase III readout, which showed weight loss that fell short of Novo Nordisks prior projections for the therapy